MetaCap

Insight Molecular Diagnostics Inc. (IMDX)

NASDAQ: IMDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

1.97+0.31 (+18.67%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IMDX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$80.88M
EPS (TTM)
-$1.27
52-week range
1.50 – 7.51
Day range
1.62 – 2.01
Volume / Avg
1.20M / 261.88K
Beta
—

52-week range

$1.50$7.51

IMDX stock today

On Nov 20, IMDX ended the session at $1.97, adding $0.31 (18.67%), versus the S&P 500's 3.70% decline. Volume was 4.6x the average at 1.20M shares, a sign of unusually heavy trading. At this level, IMDX sits near the bottom of its 52-week range of $1.50 to $7.51: 73.8% below the high, set on Dec 31, 2025 and 31.3% above the low.

IMDX is down 73.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.4%. Insight Molecular Diagnostics has posted a net loss over the last twelve months (EPS of -$1.27), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Insight Molecular Diagnostics

Company profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. Joshua Riggs
Headquarters
Nashville, TN
Employees
55

Financial highlights

Full financials

In fiscal 2025, Insight Molecular Diagnostics generated $4.1 million in revenue, up 115.6% from fiscal 2024, its 3rd consecutive year of revenue growth. Insight Molecular Diagnostics reported a net loss of $50.2 million, compared with a loss of $60.7 million a year earlier. Gross margin was 56.7% (up from 39.3%) and operating margin -1260.8%.

Insight Molecular Diagnostics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$4.05M$1.88M$1.50M$958.00K$2.20M
Growth+115.58%+25.15%+56.89%-56.41%+80.76%
Net income$-50.22M$-60.66M$-27.78M$-72.90M$-64.10M
EPS (diluted)$-1.65$-4.66$-3.75$-13.25$-0.72

Analyst forecast

Forecast

Consensus (5 analysts)

buy

Avg. price target

$8.25+318.78%

  • Strong buy 1
  • Buy 2
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.34 vs —

IMDX news

All IMDX news

Insight Molecular Diagnostics peers

Health Care sector
IMDX peer companies
CompanyPrice% ChgMarket capCompare
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs IMDX
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs IMDX
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs IMDX
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs IMDX
BMRABiomerica Inc.1.08-0.92%$4.97Mvs IMDX
CDIOCardio Diagnostics Holdings Inc.1.60-3.03%$4.74Mvs IMDX
QCLSQ/C Technologies Inc.0.2784-6.01%$2.40Mvs IMDX
VRAXVirax Biolabs Group Limited0.3319-12.89%$446.40Kvs IMDX

Indexes, lists and sector

Insight Molecular Diagnostics stock FAQ

What is Insight Molecular Diagnostics's stock price today?

IMDX last traded at $1.97 as of Nov 20, 4:00 PM EST, up 18.67% on the day. Prices are delayed at least 15 minutes.

Does Insight Molecular Diagnostics pay a dividend?

No. Insight Molecular Diagnostics does not currently pay a regular cash dividend.

Who is Insight Molecular Diagnostics's CEO?

Mr. Joshua Riggs is the chief executive officer of Insight Molecular Diagnostics Inc., which has about 55 employees.

Has IMDX ever split its stock?

Yes. The most recent IMDX stock split was a 1-for-20 split on Jul 25, 2023.

What is the IMDX 52-week high?

The 52-week high for IMDX is $7.51 and the 52-week low is $1.50. The stock is currently 73.8% below its high.

Compare IMDX